S. E. Akhan, E. Yavuz, A. Tecer, C. A. Iyibozkurt, S. Topuz et al., The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study, Gynecologic Oncology, vol.99, issue.1, pp.36-42, 2005.
DOI : 10.1016/j.ygyno.2005.05.019

F. Amant, A. Coosemans, M. Debiec-rychter, D. Timmerman, and I. Vergote, Clinical management of uterine sarcomas, The Lancet Oncology, vol.10, issue.12, pp.1188-1198, 2009.
DOI : 10.1016/S1470-2045(09)70226-8

F. Amant, M. De-la-rey, C. M. Dorfling, L. Van-der-walt, G. Dreyer et al., PTEN Mutations in Uterine Sarcomas, Gynecologic Oncology, vol.85, issue.1, pp.165-169, 2002.
DOI : 10.1006/gyno.2002.6601

R. Arend, M. Bagaria, S. N. Lewin, X. Sun, I. Deutsch et al., Long-term outcome and natural history of uterine adenosarcomas, Gynecologic Oncology, vol.119, issue.2, pp.305-308, 2010.
DOI : 10.1016/j.ygyno.2010.07.001

K. Baird, S. Davis, C. R. Antonescu, U. L. Harper, R. L. Walker et al., Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma Biology, Cancer Research, vol.65, issue.20, pp.9226-9235, 2005.
DOI : 10.1158/0008-5472.CAN-05-1699

R. R. Barakat, M. Markman, R. , and M. , Principles and practice of gynecologic oncology, 2009.

K. T. Barker, S. Bevan, R. Wang, Y. Lu, A. M. Flanagan et al., Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas, British Journal of Cancer, vol.87, issue.4, pp.446-448, 2002.
DOI : 10.1038/sj.bjc.6600502

A. H. Beck, C. Lee, D. M. Witten, B. C. Gleason, B. Edris et al., Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling, Oncogene, vol.3, issue.6, pp.845-854, 2010.
DOI : 10.1198/106186006X113430

S. W. Bell, R. L. Kempson, and M. R. Hendrickson, Problematic Uterine Smooth Muscle Neoplasms, The American Journal of Surgical Pathology, vol.18, issue.6, pp.535-558, 1994.
DOI : 10.1097/00000478-199406000-00001

D. Botsis, C. Koliopoulos, A. Kondi-pafitis, C. , and G. , Myxoid Leiomyosarcoma of the Uterus in a Patient Receiving Tamoxifen Therapy: A Case Report, International Journal of Gynecological Pathology, vol.25, issue.2, pp.173-175, 2006.
DOI : 10.1097/01.pgp.0000185407.93308.ce

S. E. Brooks, M. Zhan, T. Cote, and C. R. Baquet, Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma, 1989.

A. L. Cesne, J. Y. Blay, I. Judson, A. V. Oosterom, J. Verweij et al., Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial, Journal of Clinical Oncology, vol.23, issue.3, pp.576-584, 2005.
DOI : 10.1200/JCO.2005.01.180

G. Chaplain, J. Cuisenier, C. Milan, M. Smail, P. Janoray et al., [Cancers of the corpus uteri on the Côte-d'Or 1982-1990. Incidence, clinical stage and survival], Bull Cancer, vol.81, pp.691-697, 1994.

L. Chauveinc, E. Deniaud, C. Plancher, X. Sastre, F. Amsani et al., Uterine Sarcomas: The Curie Institut Experience. Prognosis Factors and Adjuvant Treatments, Gynecologic Oncology, vol.72, issue.2, pp.232-237, 1999.
DOI : 10.1006/gyno.1998.5251

S. P. Chawla, J. Blay, I. L. Ray-coquard, L. Cesne, A. Staddon et al., Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) ASCO Meeting Abstracts 29, 2011.

Y. L. Cho, S. Bae, M. S. Koo, K. M. Kim, H. Chun et al., Array comparative genomic hybridization analysis of uterine leiomyosarcoma, Gynecologic Oncology, vol.99, issue.3, pp.545-551, 2005.
DOI : 10.1016/j.ygyno.2005.07.017

H. Choi, C. Charnsangavej, S. C. Faria, H. A. Macapinlac, M. A. Burgess et al., Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria, Journal of Clinical Oncology, vol.25, issue.13, pp.1753-1759, 2007.
DOI : 10.1200/JCO.2006.07.3049

W. M. Christopherson, E. O. Williamson, and L. A. Gray, Leiomyosarcoma of the uterus, Cancer, vol.29, issue.6, pp.1512-1517, 1972.
DOI : 10.1002/1097-0142(197206)29:6<1512::AID-CNCR2820290615>3.0.CO;2-K

A. Coosemans, B. Van-calster, G. Verbist, P. Moerman, I. Vergote et al., Wilms Tumor Gene 1 (WT1) is a Prognostic Marker in High-Grade Uterine Sarcoma, International Journal of Gynecological Cancer, vol.21, pp.302-308, 2011.
DOI : 10.1097/IGC.0b013e318207cab5

S. F. Cramer, P. M. Newcomb, and T. A. Bonfiglio, Myometrial dysplasia (atypical myometrial hyperplasia), Human Pathology, vol.38, issue.4, pp.652-655, 2007.
DOI : 10.1016/j.humpath.2007.01.010

J. Currie, J. A. Blessing, H. B. Muss, J. Fowler, M. Berman et al., Combination Chemotherapy with Hydroxyurea, Dacarbazine (DTIC), and Etoposide in the Treatment of Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study, Gynecologic Oncology, vol.61, issue.1, pp.27-30, 1996.
DOI : 10.1006/gyno.1996.0091

D. Angelo, E. Espinosa, I. Ali, R. Gilks, C. B. Rijn et al., Uterine leiomyosarcomas: Tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis, Gynecologic Oncology, vol.121, issue.2, pp.328-333, 2011.
DOI : 10.1016/j.ygyno.2011.01.022

D. Angelo, E. Prat, and J. , Uterine sarcomas: A review, Gynecologic Oncology, vol.116, issue.1, pp.131-139, 2010.
DOI : 10.1016/j.ygyno.2009.09.023

S. Delaloge, P. Pautier, and P. Duvillard, Tamoxifen-related uterine malignancies: carcinomas or sarcomas?, International Journal of Gynecological Cancer, vol.14, issue.2, p.395, 2004.
DOI : 10.1111/j.1048-891X.2004.014229.x

D. Denschlag, I. Masoud, G. Stanimir, G. , and L. , Prognostic factors and outcome in women with uterine sarcoma, European Journal of Surgical Oncology (EJSO), vol.33, issue.1, pp.91-95, 2007.
DOI : 10.1016/j.ejso.2006.11.012

J. Duclos, A. Valent, G. Malouf, F. Drusch, N. Auger et al., in 67 cases of endometrial stromal tumors collected in a tissue microarray., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.10069, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.10069

P. Duvillard, Pathologie gyn??cologique. Cas no??7. Tumeur musculaire lisse ut??rine de malignit?? incertaine (STUMP), Annales de Pathologie, vol.32, issue.3, pp.211-213, 2012.
DOI : 10.1016/j.annpat.2012.04.007

J. H. Edmonson, J. A. Blessing, J. A. Cosin, D. S. Miller, D. E. Cohn et al., Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study, Gynecologic Oncology, vol.85, issue.3, pp.507-510, 2002.
DOI : 10.1006/gyno.2002.6661

M. H. Einstein, R. R. Barakat, D. S. Chi, Y. Sonoda, K. M. Alektiar et al., Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease, International Journal of Gynecological Cancer, vol.18, issue.5, pp.1065-1070, 2008.
DOI : 10.1111/j.1525-1438.2007.01126.x

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

I. Espinosa, A. H. Beck, C. Lee, S. Zhu, K. D. Montgomery et al., Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma, The American Journal of Pathology, vol.174, issue.6, pp.2347-2356, 2009.
DOI : 10.2353/ajpath.2009.081037

H. L. Evans, S. P. Chawla, C. Simpson, and K. P. Finn, Smooth muscle neoplasms of the uterus other than ordinary leiomyoma: A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors, Cancer, vol.36, issue.10, pp.2239-2247, 1988.
DOI : 10.1002/1097-0142(19881115)62:10<2239::AID-CNCR2820621028>3.0.CO;2-Y

E. Fox, B. C. Widemann, D. S. Hawkins, N. Jayaprakash, R. Dagher et al., Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas, Clinical Cancer Research, vol.15, issue.23, pp.7361-7367, 2009.
DOI : 10.1158/1078-0432.CCR-09-0761

M. A. Geller, P. Argenta, W. Bradley, K. E. Dusenbery, D. Brooker et al., Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression, Gynecologic Oncology, vol.95, issue.3, pp.632-636, 2004.
DOI : 10.1016/j.ygyno.2004.07.049

R. L. Giuntoli, D. S. Metzinger, C. S. Dimarco, S. S. Cha, J. A. Sloan et al., Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy???, Gynecologic Oncology, vol.89, issue.3, pp.460-469, 2003.
DOI : 10.1016/S0090-8258(03)00137-9

A. M. Goh, C. R. Coffill, L. , and D. P. , The role of mutant p53 in human cancer, The Journal of Pathology, vol.12, issue.2, pp.116-126, 2011.
DOI : 10.1002/path.2784

W. T. Van-der-graaf, J. Blay, S. P. Chawla, D. Kim, B. Bui-nguyen et al., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, vol.379, issue.9829, pp.1879-1886, 2012.
DOI : 10.1016/S0140-6736(12)60651-5

M. D. Green, H. Koelbl, J. Baselga, A. Galid, V. Guillem et al., A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy, Annals of Oncology, vol.14, issue.1, pp.29-35, 2003.
DOI : 10.1093/annonc/mdg019

B. Greer and W. Koh, NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (National Comprehensive Cancer Network), 2012.

K. L. Hall, M. G. Teneriello, R. R. Taylor, S. Lemon, M. Ebina et al., Analysis of Ki-ras, p53, and MDM2 Genes in Uterine Leiomyomas and Leiomyosarcomas, Gynecologic Oncology, vol.65, issue.2, pp.330-335, 1997.
DOI : 10.1006/gyno.1997.4653

E. V. Hannigan, R. S. Freedman, R. , and F. N. , Adjuvant chemotherapy in early uterine sarcoma, Gynecologic Oncology, vol.15, issue.1, pp.56-64, 1983.
DOI : 10.1016/0090-8258(83)90117-8

B. L. Harlow, N. S. Weiss, and S. Lofton, The epidemiology of sarcomas of the uterus, J. Natl. Cancer Inst, vol.76, pp.399-402, 1986.

M. L. Hensley, J. A. Blessing, K. Degeest, O. Abulafia, P. G. Rose et al., Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study, Gynecologic Oncology, vol.109, issue.3, pp.323-328, 2008.
DOI : 10.1016/j.ygyno.2008.02.024

M. L. Hensley, J. A. Blessing, R. Mannel, R. , and P. G. , Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial, Gynecologic Oncology, vol.109, issue.3, pp.329-334, 2008.
DOI : 10.1016/j.ygyno.2008.03.010

M. L. Hensley, J. A. Blessing, R. Mannel, R. , and P. G. , Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial, Gynecologic Oncology, vol.109, issue.3, pp.329-334, 2008.
DOI : 10.1016/j.ygyno.2008.03.010

M. L. Hensley, N. Ishill, R. Soslow, J. Larkin, N. Abu-rustum et al., Adjuvant gemcitabine plus docetaxel for completely resected stages I???IV high grade uterine leiomyosarcoma: Results of a prospective study, Gynecologic Oncology, vol.112, issue.3, pp.563-567, 2009.
DOI : 10.1016/j.ygyno.2008.11.027

M. L. Hensley, M. W. Sill, D. R. Scribner, . Jr, J. Brown et al., Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study, Gynecologic Oncology, vol.115, issue.3, pp.460-465, 2009.
DOI : 10.1016/j.ygyno.2009.09.011

E. Hernando, E. Charytonowicz, M. E. Dudas, S. Menendez, I. Matushansky et al., The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas, Nature Medicine, vol.18, issue.6, pp.748-753, 2007.
DOI : 10.1038/nm1560

N. B. Hornback, G. Omura, and F. J. Major, Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma, International Journal of Radiation Oncology*Biology*Physics, vol.12, issue.12, pp.2127-2130, 1986.
DOI : 10.1016/0360-3016(86)90011-8

A. Iasonos, E. Keung, O. Zivanovic, R. Mancari, M. Peiretti et al., External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS) ASCO Meeting Abstracts 30, p.5090, 2012.

Y. J. Ioffe, A. J. Li, C. S. Walsh, B. Y. Karlan, R. Leuchter et al., Hormone receptor expression in uterine sarcomas: Prognostic and therapeutic roles, Gynecologic Oncology, vol.115, issue.3, pp.466-471, 2009.
DOI : 10.1016/j.ygyno.2009.08.014

D. S. Kapp, J. Y. Shin, C. , and J. K. , Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas, Cancer, vol.92, issue.4, pp.820-830, 2008.
DOI : 10.1002/cncr.23245

T. W. Kelley, E. C. Borden, and J. R. Goldblum, Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas, Applied Immunohistochemistry & Molecular Morphology, vol.12, issue.4, pp.338-341, 2004.
DOI : 10.1097/00129039-200412000-00008

W. Y. Kim, S. Chang, K. Chang, J. Yoon, J. H. Kim et al., Uterine Leiomyosarcoma : 14-year Two-center Experience of 31 Cases, Cancer Research and Treatment, vol.41, issue.1, pp.24-28, 2009.
DOI : 10.4143/crt.2009.41.1.24

I. Kloos, S. Delaloge, P. Pautier, D. Palma, M. Goupil et al., Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature, International Journal of Gynecological Cancer, vol.12, issue.5, 2002.
DOI : 10.1046/j.1525-1438.2002.01134.x

J. I. Koontz, A. L. Soreng, M. Nucci, F. C. Kuo, P. Pauwels et al., Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors, Proc. Natl. Acad. Sci. U.S.A. 98, pp.6348-6353, 2001.
DOI : 10.1073/pnas.101132598

T. C. Krivak, J. D. Seidman, J. W. Mcbroom, P. J. Mackoul, L. M. Aye et al., Uterine Adenosarcoma with Sarcomatous Overgrowth versus Uterine Carcinosarcoma: Comparison of Treatment and Survival, Gynecologic Oncology, vol.83, issue.1, pp.89-94, 2001.
DOI : 10.1006/gyno.2001.6334

D. M. Kushner, K. D. Webster, J. L. Belinson, L. A. Rybicki, A. W. Kennedy et al., Safety and Efficacy of Adjuvant Single-Agent Ifosfamide in Uterine Sarcoma, Gynecologic Oncology, vol.78, issue.2, pp.221-227, 2000.
DOI : 10.1006/gyno.2000.5875

B. Larson, C. Silfverswärd, B. Nilsson, and F. Pettersson, Prognostic Factors in Uterine Leiomyosarcoma: A Clinical and Histopathological Study of 143 Cases the Radiumhemmet Series 1936-1981, Acta Oncologica, vol.114, issue.2, pp.185-191, 1990.
DOI : 10.3109/02841869009126543

C. Lee, W. Ou, A. Mariño-enriquez, M. Zhu, M. Mayeda et al., 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma, Proc. Natl. Acad. Sci. U.S.A. 109, pp.929-934, 2012.
DOI : 10.1073/pnas.1115528109

Y. Lee, M. John, S. Edwards, J. Clark, P. Flohr et al., Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling, British Journal of Cancer, vol.88, issue.4, pp.510-515, 2003.
DOI : 10.1038/sj.bjc.6600766

Y. Lee, M. John, A. Falconer, S. Edwards, J. Clark et al., A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas, Cancer Research, vol.64, issue.20, pp.7201-7204, 2004.
DOI : 10.1158/0008-5472.CAN-04-1673

H. J. Lehtonen, M. Kiuru, S. K. Ylisaukko-oja, R. Salovaara, R. Herva et al., Increased risk of cancer in patients with fumarate hydratase germline mutation, Journal of Medical Genetics, vol.43, issue.6, pp.523-526, 2006.
DOI : 10.1136/jmg.2005.036400

M. M. Leitao, M. F. Brennan, M. Hensley, Y. Sonoda, A. Hummer et al., Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma, Gynecologic Oncology, vol.87, issue.3, pp.287-294, 2002.
DOI : 10.1006/gyno.2002.6840

M. M. Leitao, . Jr, M. L. Hensley, R. R. Barakat, C. Aghajanian et al., Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma, Gynecologic Oncology, vol.124, issue.3, pp.558-562, 2012.
DOI : 10.1016/j.ygyno.2011.11.009

M. M. Leitao, . Jr, O. Zivanovic, D. S. Chi, M. L. Hensley et al., Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis, Gynecologic Oncology, vol.125, issue.2, pp.409-413, 2012.
DOI : 10.1016/j.ygyno.2012.02.014

M. M. Leitao, R. A. Soslow, D. Nonaka, A. B. Olshen, C. Aghajanian et al., Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma, Cancer, vol.155, issue.6, pp.1455-1462, 2004.
DOI : 10.1002/cncr.20521

F. Leung, J. Terzibachian, C. Gay, C. Fat, B. Aouar et al., Hyst??rectomies pour l??iomyomes pr??sum??s??: la crainte du l??iomyosarcome doit-elle faire appr??hender la voie d???abord chirurgicale autre que laparotomique???, Gyn??cologie Obst??trique & Fertilit??, vol.37, issue.2, pp.109-114, 2009.
DOI : 10.1016/j.gyobfe.2008.09.022

F. Levi, L. Vecchia, C. Randimbison, L. Te, and V. , Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland, European Journal of Cancer, vol.35, issue.12, pp.1711-1716, 1999.
DOI : 10.1016/S0959-8049(99)00179-3

H. J. Long, J. A. Blessing, and J. Sorosky, Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: A Gynecologic Oncology Group study, Gynecologic Oncology, vol.99, issue.2, pp.339-342, 2005.
DOI : 10.1016/j.ygyno.2005.06.002

H. J. Mackay, R. J. Buckanovich, H. Hirte, R. Correa, P. Hoskins et al., A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia, Gynecologic Oncology, vol.125, issue.1, pp.136-140, 2012.
DOI : 10.1016/j.ygyno.2011.11.042

A. Mahdavi, B. J. Monk, J. Ragazzo, M. I. Hunter, S. E. Lentz et al., Pelvic Radiation Improves Local Control After Hysterectomy for Uterine Leiomyosarcoma, International Journal of Gynecological Cancer, vol.108, issue.6, pp.1080-1084, 2009.
DOI : 10.1111/IGC.0b013e3181acae50

G. G. Malouf, J. Duclos, A. Rey, P. Duvillard, V. Lazar et al., Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma, Annals of Oncology, vol.21, issue.10, pp.2102-2106, 2010.
DOI : 10.1093/annonc/mdq064

K. Mayerhofer, A. Obermair, G. Windbichler, E. Petru, A. Kaider et al., Leiomyosarcoma of the Uterus: A Clinicopathologic Multicenter Study of 71 Cases, Gynecologic Oncology, vol.74, issue.2, pp.196-201, 1999.
DOI : 10.1006/gyno.1999.5436

M. Von-mehren, C. Rankin, J. R. Goldblum, G. D. Demetri, V. Bramwell et al., Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas, Cancer, vol.23, issue.3, pp.770-776, 2012.
DOI : 10.1002/cncr.26334

L. A. Meza-zepeda, S. H. Kresse, A. H. Barragan-polania, B. Bjerkehagen, H. O. Ohnstad et al., Array Comparative Genomic Hybridization Reveals Distinct DNA Copy Number Differences between Gastrointestinal Stromal Tumors and Leiomyosarcomas, Cancer Research, vol.66, issue.18, pp.8984-8993, 2006.
DOI : 10.1158/0008-5472.CAN-06-1972

F. Micci, I. Panagopoulos, B. Bjerkehagen, and S. Heim, Consistent Rearrangement of Chromosomal Band 6p21 with Generation of Fusion Genes JAZF1/PHF1 and EPC1/PHF1 in Endometrial Stromal Sarcoma, Cancer Research, vol.66, issue.1, pp.107-112, 2006.
DOI : 10.1158/0008-5472.CAN-05-2485

D. S. Miller, J. A. Blessing, L. C. Kilgore, R. Mannel, V. Le et al., Phase II Trial of Topotecan in Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas, American Journal of Clinical Oncology: Cancer Clinical Trials, vol.23, issue.4, pp.355-357, 2000.
DOI : 10.1097/00000421-200008000-00009

K. Mittal and A. Joutovsky, Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas, Gynecologic Oncology, vol.104, issue.2, pp.362-365, 2007.
DOI : 10.1016/j.ygyno.2006.08.034

K. R. Mittal, F. Chen, J. J. Wei, K. Rijhvani, R. Kurvathi et al., Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas, Modern Pathology, vol.62, issue.10, pp.1303-1311, 2009.
DOI : 10.1002/(SICI)1096-8628(19990326)89:1<23::AID-AJMG6>3.0.CO;2-#

K. Miyajima, S. Tamiya, Y. Oda, T. Adachi, T. Konomoto et al., Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction, Cancer Letters, vol.164, issue.2, pp.177-188, 2001.
DOI : 10.1016/S0304-3835(00)00607-8

B. J. Monk, J. A. Blessing, D. G. Street, C. Y. Muller, J. J. Burke et al., A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study, Gynecologic Oncology, vol.124, issue.1, pp.48-52, 2012.
DOI : 10.1016/j.ygyno.2011.09.019

P. Morice, A. Rodrigues, P. Pautier, A. Rey, S. Camatte et al., Chirurgie des sarcomes ut??rins : revue de la litt??rature et recommandations sur la prise en charge chirurgicale, Gyn??cologie Obst??trique & Fertilit??, vol.31, issue.2, pp.147-150, 2003.
DOI : 10.1016/S1297-9589(03)00061-4

P. Morice, A. Rodriguez, A. Rey, P. Pautier, D. Atallah et al., Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients, Eur. J. Gynaecol. Oncol, vol.24, pp.237-240, 2003.

H. B. Muss, B. Bundy, P. J. Disaia, H. D. Homesley, W. C. Fowler et al., Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicinVersus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group), Cancer, vol.34, issue.8, pp.1648-1653, 1985.
DOI : 10.1002/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7

H. B. Muss, B. N. Bundy, L. Adcock, and J. Beecham, Mitoxantrone in the Treatment of Advanced Uterine Sarcoma, American Journal of Clinical Oncology, vol.13, issue.1, pp.32-34, 1990.
DOI : 10.1097/00000421-199002000-00009

T. O. Nielsen, R. B. West, S. C. Linn, O. Alter, M. A. Knowling et al., Molecular characterisation of soft tissue tumours: a gene expression study, The Lancet, vol.359, issue.9314, pp.1301-1307, 2002.
DOI : 10.1016/S0140-6736(02)08270-3

T. H. Niemann, S. S. Raab, J. C. Lenel, J. R. Rodgers, R. et al., p53 protein overexpression in smooth muscle tumors of the uterus*1, Human Pathology, vol.26, issue.4, pp.375-379, 1995.
DOI : 10.1016/0046-8177(95)90136-1

R. R. Nordal and S. O. Thoresen, Uterine sarcomas in Norway 1956???1992: Incidence, survival and mortality, European Journal of Cancer, vol.33, issue.6, pp.907-911, 1997.
DOI : 10.1016/S0959-8049(97)00040-3

H. J. Norris, T. , and H. B. , Mesenchymal tumors of the uterus:III. A clinical and pathologic study of 31 carcinosarcomas, Cancer, vol.39, issue.10, pp.1459-1465, 1966.
DOI : 10.1002/1097-0142(196610)19:10<1459::AID-CNCR2820191019>3.0.CO;2-A

O. 'cearbhaill, R. Zhou, Q. Iasonos, A. Soslow, R. A. Leitao et al., Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors, Gynecologic Oncology, vol.116, issue.3, pp.424-429, 2010.
DOI : 10.1016/j.ygyno.2009.10.064

K. Odunsi, V. Moneke, J. Tammela, S. Ghamande, P. Seago et al., Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up, International Journal of Gynecological Cancer, vol.14, issue.4, pp.659-664, 2004.
DOI : 10.1111/j.1048-891X.2004.14420.x

S. Okuno, H. Bailey, M. R. Mahoney, D. Adkins, W. Maples et al., A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas, Cancer, vol.38, issue.15, 2011.
DOI : 10.1002/cncr.25928

K. S. Oláh, J. A. Dunn, and H. Gee, Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma, BJOG: An International Journal of Obstetrics and Gynaecology, vol.56, issue.4, pp.590-594, 1992.
DOI : 10.1016/0277-5379(91)90300-3

G. A. Omura, J. A. Blessing, F. Major, S. Lifshitz, C. E. Ehrlich et al., A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study., Journal of Clinical Oncology, vol.3, issue.9, 1985.
DOI : 10.1200/JCO.1985.3.9.1240

G. A. Omura, F. J. Major, J. A. Blessing, T. V. Sedlacek, J. T. Thigpen et al., A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas, Cancer, vol.3, issue.4, pp.626-632, 1983.
DOI : 10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E

A. W. Oosten, C. Seynaeve, P. I. Schmitz, M. A. Den-bakker, J. Verweij et al., Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin, Sarcoma, vol.18, issue.10, p.348910, 2009.
DOI : 10.1038/ncponc1124

J. P. Packenham, S. Du-manoir, E. Schrock, J. I. Risinger, D. Dixon et al., Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization, Molecular Carcinogenesis, vol.107, issue.4, pp.273-279, 1997.
DOI : 10.1002/(SICI)1098-2744(199708)19:4<273::AID-MC9>3.0.CO;2-D

I. Panagopoulos, F. Micci, J. Thorsen, L. Gorunova, A. M. Eibak et al., Novel Fusion of MYST/Esa1-Associated Factor 6 and PHF1 in Endometrial Stromal Sarcoma, PLoS ONE, vol.277, issue.6, p.39354, 2012.
DOI : 10.1371/journal.pone.0039354.t001

J. Park, D. Kim, D. Suh, J. Kim, Y. Kim et al., Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989???2007, Journal of Cancer Research and Clinical Oncology, vol.100, issue.12, pp.1277-1287, 1989.
DOI : 10.1007/s00432-008-0422-2

W. H. Parker, Y. S. Fu, and J. S. Berek, Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma, Obstet Gynecol, vol.83, pp.414-418, 1994.

M. I. Patrikis, E. J. Bryan, N. A. Thomas, G. E. Rice, M. A. Quinn et al., Mutation analysis ofCDP,TP53, andKRAS in uterine leiomyomas, Molecular Carcinogenesis, vol.19, issue.2, pp.61-64, 2003.
DOI : 10.1002/mc.10127

H. Patterson, S. Gill, C. Fisher, M. G. Law, H. Jayatilake et al., Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas, British Journal of Cancer, vol.69, issue.6, pp.1052-1058, 1994.
DOI : 10.1038/bjc.1994.207

P. Pautier, A. Floquet, L. Gladieff, D. Berton-rigaud, S. Piperno-neumann et al., A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients., Journal of Clinical Oncology, vol.29, issue.15_suppl, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.10022

P. Pautier, A. Floquet, N. Penel, S. Piperno-neumann, N. Isambert et al., Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study), The Oncologist, vol.17, issue.9, 2012.
DOI : 10.1634/theoncologist.2011-0467

P. Pautier, C. Genestie, K. Fizazi, P. Morice, C. Mottet et al., Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas, International Journal of Gynecological Cancer, vol.12, issue.6, pp.749-754, 2002.
DOI : 10.1046/j.1525-1438.2002.01144.x

P. Pautier, C. Genestie, K. Fizazi, P. Morice, C. Mottet et al., Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas, International Journal of Gynecological Cancer, vol.12, issue.6, pp.749-754, 2002.
DOI : 10.1046/j.1525-1438.2002.01144.x

P. Pautier, C. Genestie, A. Rey, P. Morice, B. Roche et al., Analysis of clinicopathologic prognostic factors for 157, 2000.

P. Pautier, A. Rey, C. Haie-meder, P. Kerbrat, J. L. Dutel et al., Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone, International Journal of Gynecological Cancer, vol.14, issue.6, pp.1112-1117, 2004.
DOI : 10.1111/j.1048-891X.2004.14609.x

M. Pelmus, F. Penault-llorca, L. Guillou, F. Collin, G. Bertrand et al., Prognostic Factors in Early-Stage Leiomyosarcoma of the Uterus, International Journal of Gynecological Cancer, vol.62, issue.3, pp.385-390, 2009.
DOI : 10.1111/IGC.0b013e3181a1bfbc

N. Penel, A. Italiano, N. Isambert, E. Bompas, G. Bousquet et al., Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy, Annals of Oncology, vol.21, issue.6, pp.1361-1365, 2010.
DOI : 10.1093/annonc/mdp485

W. A. Peters, D. R. Howard, W. A. Andersen, and D. C. Figge, Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential, Obstetrics & Gynecology, vol.83, issue.6, pp.1015-1020, 1994.
DOI : 10.1097/00006250-199406000-00023

M. S. Piver, T. G. Deeulis, S. B. Lele, and J. J. Barlow, Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract, Gynecologic Oncology, vol.14, issue.3, pp.319-323, 1982.
DOI : 10.1016/0090-8258(82)90106-8

M. S. Piver, S. B. Lele, D. L. Marchetti, and L. J. Emrich, Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas, Journal of Surgical Oncology, vol.23, issue.4, pp.233-239, 1988.
DOI : 10.1002/jso.2930380406

B. J. Quade, T. Wang, K. Sornberger, P. Dal-cin, G. L. Mutter et al., Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling, Genes, Chromosomes and Cancer, vol.261, issue.2, pp.97-108, 2004.
DOI : 10.1002/gcc.20018

S. Rammeh-rommani, M. Mokni, W. Stita, A. Trabelsi, S. Hamissa et al., Les tumeurs musculaires lisses de l???ut??rus, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.34, issue.6, pp.568-571, 2005.
DOI : 10.1016/S0368-2315(05)82881-9

M. R. Raspollini, M. Paglierani, G. L. Taddei, A. Villanucci, G. Amunni et al., The protooncogene c-KIT is expressed in leiomyosarcomas of the uterus, Gynecologic Oncology, vol.93, issue.3, p.718, 2004.
DOI : 10.1016/j.ygyno.2004.03.017

N. S. Reed, C. Mangioni, H. Malmström, G. Scarfone, A. Poveda et al., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874), European Journal of Cancer, vol.44, issue.6, pp.808-818, 2008.
DOI : 10.1016/j.ejca.2008.01.019

R. Sabatini, D. Fazio, F. Loizzi, and P. , Uterine leiomyosarcoma in a postmenopausal woman treated with tamoxifen: case report, Eur. J. Gynaecol. Oncol, vol.20, pp.327-328, 1999.

V. Immunolocalization-of and . Vegf, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma, Acta Histochem, vol.113, pp.317-325

L. B. Schwartz, M. P. Diamond, and P. E. Schwartz, Leiomyosarcomas: Clinical presentation, American Journal of Obstetrics and Gynecology, vol.168, issue.1, pp.180-183, 1993.
DOI : 10.1016/S0002-9378(12)90910-2

S. M. Schwartz and N. S. Weiss, Marital status and the incidence of sarcomas of the uterus, Cancer Res, vol.50, pp.1886-1889, 1990.

S. M. Schwartz, N. S. Weiss, J. R. Daling, M. D. Gammon, J. M. Liff et al., Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus, Cancer, vol.21, issue.4, pp.717-724, 1996.
DOI : 10.1002/(SICI)1097-0142(19960215)77:4<717::AID-CNCR18>3.0.CO;2-3

S. M. Schwartz, N. S. Weiss, J. R. Daling, P. A. Newcomb, J. M. Liff et al., Incidence of histologic types of uterine sarcoma in relation to menstrual and reproductive history, International Journal of Cancer, vol.53, issue.3, pp.362-367, 1991.
DOI : 10.1002/ijc.2910490308

N. Setsu, H. Yamamoto, K. Kohashi, M. Endo, S. Matsuda et al., The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas, Cancer, vol.100, issue.6, 2011.
DOI : 10.1002/cncr.26448

K. M. Skubitz and A. P. Skubitz, Differential gene expression in leiomyosarcoma, Cancer, vol.286, issue.5, pp.1029-1038, 2003.
DOI : 10.1002/cncr.11586

R. E. Slayton, J. A. Blessing, C. Angel, and M. Berman, Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study, Cancer Treat Rep, vol.71, pp.1303-1304, 1987.

S. Sleijfer, I. Ray-coquard, Z. Papai, L. Cesne, A. Scurr et al., Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer???Soft Tissue and Bone Sarcoma Group (EORTC Study 62043), Journal of Clinical Oncology, vol.27, issue.19, pp.3126-3132, 2009.
DOI : 10.1200/JCO.2008.21.3223

R. A. Soslow and E. Oliva, Uterine Cancer, Uterine Cancer: Screening, pp.51-86, 2009.
DOI : 10.1007/978-1-60327-044-1_4

G. Sutton, J. Blessing, P. Hanjani, and P. Kramer, Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Gynecologic Oncology, vol.96, issue.3, pp.749-752, 2005.
DOI : 10.1016/j.ygyno.2004.11.036

G. Sutton, J. A. Blessing, and H. Ball, Phase II Trial of Paclitaxel in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study, Gynecologic Oncology, vol.74, issue.3, pp.346-349, 1999.
DOI : 10.1006/gyno.1999.5463

G. Sutton, J. A. Blessing, and J. H. Malfetano, Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcomas of the Uterus: A Gynecologic Oncology Group Study, Gynecologic Oncology, vol.62, issue.2, pp.226-229, 1996.
DOI : 10.1006/gyno.1996.0220

G. Sutton, J. J. Kavanagh, A. Wolfson, T. , and C. , Corpus: Mesenchymal Tumors, Principles and Practice of Gynecologic Oncology, pp.733-763, 2009.

G. P. Sutton, J. A. Blessing, R. J. Barrett, and R. Mcgehee, Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study, American Journal of Obstetrics and Gynecology, vol.166, issue.2, pp.556-559, 1992.
DOI : 10.1016/0002-9378(92)91671-V

S. Takamizawa, H. Minakami, R. Usui, S. Noguchi, M. Ohwada et al., Risk of Complications and Uterine Malignancies in Women Undergoing Hysterectomy for Presumed Benign Leiomyomas, Gynecologic and Obstetric Investigation, vol.48, issue.3, pp.193-196, 1999.
DOI : 10.1159/000010172

S. M. Talbot, M. L. Keohan, M. Hesdorffer, R. Orrico, E. Bagiella et al., A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma, Cancer, vol.20, issue.9, pp.1942-1946, 2003.
DOI : 10.1002/cncr.11730

F. A. Tavassoli and P. Devilee, Chapter 4 Tumours of the uterine corpus World Health Organization Classification of Tumours), Pathology and Genetics of Tumours of the Breast and Female Genital Organs, pp.217-257, 2003.

J. T. Thigpen, J. A. Blessing, J. W. Orr, . Jr, and P. J. Disaia, Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study, Cancer Treat Rep, vol.70, pp.271-274, 1986.

I. P. Tomlinson, N. A. Alam, A. J. Rowan, E. Barclay, E. E. Jaeger et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4, pp.406-410, 2002.
DOI : 10.1038/ng849

M. Trojani, G. Contesso, J. M. Coindre, J. Rouesse, N. B. Bui et al., Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system, International Journal of Cancer, vol.2, issue.1, pp.37-42, 1984.
DOI : 10.1002/ijc.2910330108

S. De-vos, S. P. Wilczynski, M. Fleischhacker, and P. Koeffler, p53 Alterations in Uterine Leiomyosarcomas versus Leiomyomas, Gynecologic Oncology, vol.54, issue.2, pp.205-208, 1994.
DOI : 10.1006/gyno.1994.1194

J. D. Wright, V. E. Seshan, M. Shah, P. B. Schiff, W. M. Burke et al., The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma, American Journal of Obstetrics and Gynecology, vol.199, issue.5, pp.1-8, 2008.
DOI : 10.1016/j.ajog.2008.04.019

T. Wu, T. Chang, S. Hsueh, K. Hsu, H. Chou et al., Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma, Gynecologic Oncology, vol.100, issue.1, pp.166-172, 2006.
DOI : 10.1016/j.ygyno.2005.08.010

J. Yang, X. Du, K. Chen, A. Ylipää, A. J. Lazar et al., Genetic aberrations in soft tissue leiomyosarcoma, Cancer Letters, vol.275, issue.1, pp.1-8, 2009.
DOI : 10.1016/j.canlet.2008.06.013

S. K. Ylisaukko?oja, M. Kiuru, H. J. Lehtonen, R. Lehtonen, E. Pukkala et al., Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients, International Journal of Cancer, vol.52, issue.2, pp.283-287, 2006.
DOI : 10.1002/ijc.21798

O. Zivanovic, L. M. Jacks, A. Iasonos, M. M. Leitao, . Jr et al., A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma, Cancer, vol.101, issue.suppl 1, pp.660-669, 2012.
DOI : 10.1002/cncr.26333

O. Zivanovic, M. M. Leitao, A. Iasonos, L. M. Jacks, Q. Zhou et al., Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems, Journal of Clinical Oncology, vol.27, issue.12, pp.2066-2072, 2009.
DOI : 10.1200/JCO.2008.19.8366